Simmons Bank Has $7.20 Million Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Simmons Bank reduced its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 0.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 14,645 shares of the medical equipment provider’s stock after selling 50 shares during the quarter. Simmons Bank’s holdings in Intuitive Surgical were worth $7,195,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Ridgewood Investments LLC acquired a new stake in shares of Intuitive Surgical in the 2nd quarter valued at about $26,000. Godsey & Gibb Inc. raised its position in Intuitive Surgical by 140.0% in the 3rd quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 35 shares during the last quarter. Creekmur Asset Management LLC lifted its stake in Intuitive Surgical by 200.0% in the 1st quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 42 shares in the last quarter. LGT Financial Advisors LLC boosted its position in Intuitive Surgical by 415.4% during the 2nd quarter. LGT Financial Advisors LLC now owns 67 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 54 shares during the last quarter. Finally, Delos Wealth Advisors LLC grew its stake in shares of Intuitive Surgical by 380.0% during the 1st quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock worth $29,000 after acquiring an additional 57 shares in the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Citigroup increased their target price on shares of Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a report on Thursday, August 22nd. Raymond James raised their price objective on Intuitive Surgical from $500.00 to $540.00 and gave the company an “outperform” rating in a report on Monday, October 14th. Mizuho upped their target price on Intuitive Surgical from $440.00 to $500.00 in a report on Thursday, October 17th. Leerink Partners raised their price target on Intuitive Surgical from $489.00 to $502.00 in a research note on Thursday, October 17th. Finally, Barclays upped their price objective on Intuitive Surgical from $430.00 to $490.00 and gave the stock an “overweight” rating in a research note on Thursday, July 18th. One research analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $513.74.

Insider Activity at Intuitive Surgical

In other news, insider Jamie Samath sold 269 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $539.89, for a total transaction of $145,230.41. Following the completion of the sale, the insider now owns 8,757 shares of the company’s stock, valued at approximately $4,727,816.73. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, EVP Brian Edward Miller sold 2,553 shares of the firm’s stock in a transaction that occurred on Tuesday, October 22nd. The shares were sold at an average price of $515.00, for a total value of $1,314,795.00. Following the sale, the executive vice president now directly owns 7,066 shares in the company, valued at approximately $3,638,990. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Jamie Samath sold 269 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $539.89, for a total transaction of $145,230.41. Following the transaction, the insider now owns 8,757 shares of the company’s stock, valued at approximately $4,727,816.73. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 91,178 shares of company stock valued at $45,897,071 over the last quarter. 0.80% of the stock is owned by corporate insiders.

Intuitive Surgical Stock Performance

ISRG opened at $537.07 on Wednesday. The stock has a fifty day moving average of $495.85 and a 200-day moving average of $455.08. Intuitive Surgical, Inc. has a fifty-two week low of $281.12 and a fifty-two week high of $542.59. The company has a market capitalization of $191.29 billion, a P/E ratio of 86.35, a P/E/G ratio of 5.27 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings results on Thursday, October 17th. The medical equipment provider reported $1.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.24 by $0.32. The business had revenue of $2.04 billion for the quarter, compared to the consensus estimate of $2.01 billion. Intuitive Surgical had a return on equity of 13.41% and a net margin of 28.51%. On average, equities research analysts predict that Intuitive Surgical, Inc. will post 5.45 earnings per share for the current fiscal year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.